MedTrace Logo

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

NCT02330380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2017-10-13

No results posted yet for this study

Summary

This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events.

The final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time.

Secondary outcomes will assess changes in coronary artery calcification scoring, PET-MRI, skin biopsies, and clinical improvement.

Conditions

Interventions

DRUG

Methotrexate

Subjects will receive Methotrexate as detailed in the "Group" description.

DRUG

Ustekinumab

Subjects will receive Ustekinumab as detailed in the "Group" description.

DRUG

Etanercept

Subjects will receive Etanercept as detailed in the "Group" description.

DRUG

Adalimumab

Subjects will receive Adalimumab as detailed in the "Group" description.

DRUG

Acitretin

Subjects will receive Acitretin as detailed in the "Group" description.

OTHER

UVB Excimer Laser

Subjects will receive UVB Excimer Laser therapy as detailed in the "Group" description.

OTHER

Narrowband UVB

Subjects will receive Narrowband UVB as detailed in the "Group" description.

Sponsors & Collaborators

  • National Psoriasis Foundation

    collaborator OTHER

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Neil Korman, MD · University Hospitals Cleveland Medical Center

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02330380 on ClinicalTrials.gov